Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 959-964

  Talaulikar, Dipti ^a   Choudhury, Ayesha ^b   Shadbolt, Bruce ^a   Brown, Michael ^a  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

Author keywords

Diffuse large B cell lymphoma; International prognostic index; Lymphocytopenia; Non Hodgkin lymphoma; Survival

Indexed keywords

ANTHRACYCLINE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CORRELATIONAL STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; FEMALE; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 46749131276     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801959026     Document Type: Article

References (29)

1. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
2. Coiffier, B. (2005) State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol, 23, pp. 6387-6393.
3. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. and Mize, E. M. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
4. Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. and Klasa, R. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, pp. 5027-5033.
5. Rueda, A., Sabin, P., Rifa, J., Llanos, M., Gomez-Codina, J. and Lobo, F. (2007) R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: A multicentre, prospective study. Hematol Oncol
6. Shipp, M. A., Harrington, D. P., Anderson, J. R., Armitage, J. O., Bonadonna, G. and Brittinger, G. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
7. Hawkins, C. A., Collignon, P., Adams, D. N., Bowden, F. J. and Cook, M. C. (2006) Profound lymphopenia and bacteraemia. Intern Med J, 36, pp. 385-388.
8. Heimann, T. M., Bolnick, K. and Aufses Jr., A. H. (1986) Prognostic significance of severe preoperative lymphopenia in patients with Crohn's disease. Ann Surg, 203, pp. 132-135.
9. Rudiger, A., Burckhardt, O. A., Harpes, P., Muller, S. A. and Follath, F. (2006) The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med, 24, pp. 451-454.
10. Behl, D., Porrata, L. F., Markovic, S. N., Letendre, L., Pruthi, R. K. and Hook, C. C. (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia, 20, pp. 29-34.
11. Porrata, L. F., Gertz, M. A., Inwards, D. J., Litzow, M. R., Lacy, M. Q. and Tefferi, A. (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 98, pp. 579-585.
12. Siddiqui, M., Ristow, K., Markovic, S. N., Witzig, T. E., Habermann, T. M. and Colgan, J. P. (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol, 134, pp. 596-601.
13. Behl, D., Ristow, K., Markovic, S. N., Witzig, T. E., Habermann, T. M. and Colgan, J. P. (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol, 137, pp. 409-415.
14. Bierman, P. J., Lynch, J. C., Bociek, R. G., Whalen, V. L., Kessinger, A. and Vose, J. M. (2002) The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol, 13, pp. 1370-1377.
15. Kim, D. H., Baek, J. H., Chae, Y. S., Kim, Y. K., Kim, H. J. and Park, Y. H. (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia, 21, pp. 2227-2230.
16. Smithers, D. W. (1971) Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). Cancer Res, 31, pp. 1869-1870.
17. Ray-Coquard, I., Ghesquiere, H., Bachelot, T., Borg, C., Biron, P. and Sebban, C. (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer, 85, pp. 816-822.
18. Conlan, M. G., Bast, M., Armitage, J. O. and Weisenburger, D. D. (1990) Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol, 8, pp. 1163-1172.
19. Blay, J. Y., Chauvin, F., Le Cesne, A, Anglaret, B., Bouhour, D. and Lasset, C. (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol, 14, pp. 636-643.
20. Lachenal, F., Berger, F., Ghesquieres, H., Biron, P., Hot, A. and Callet-Bauchu, E. (2007) Angioimmunoblastic T-cell lymphoma: Clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore), 86, pp. 282-292.
21. Bone, R. C. (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med, 24, pp. 1125-1128.
22. Fauci, A. S. (1975) Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow. Immunology, 28, pp. 669-680.
23. Treacy, M., Lai, L., Costello, C. and Clark, A. (1987) Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br J Haematol, 65, pp. 289-294.
24. Stebbing, J., Sawleshwarkar, S., Michailidis, C., Jones, R., Bower, M. and Mandalia, S. (2005) Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med J, 81, pp. 586-588.
25. Kim, R., Emi, M., Tanabe, K. and Arihiro, K. (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, 66, pp. 5527-5536.
26. Choi, C. W., Sung, H. J., Park, K. H., Yoon, S. Y., Kim, S. J. and Oh, S. C. (2003) Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol, 73, pp. 263-266.
27. Ray-Coquard, I., Borg, C., Bachelot, T., Sebban, C., Philip, I. and Clapisson, G. (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer, 88, pp. 181-186.
28. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E. and Raab, R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, pp. 435-445.
29. Cartron, G., Watier, H., Golay, J. and Solal-Celigny, P. (2004) From the bench to the bedside: Ways to improve rituximab efficacy. Blood, 104, pp. 2635-2642.